<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8800478</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1990</journal-id>
<journal-id journal-id-type="nlm-ta">Brain Behav Immun</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Behav. Immun.</journal-id>
<journal-title-group>
<journal-title>Brain, behavior, and immunity</journal-title>
</journal-title-group>
<issn pub-type="ppub">0889-1591</issn>
<issn pub-type="epub">1090-2139</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29567371</article-id>
<article-id pub-id-type="pmc">6206432</article-id>
<article-id pub-id-type="doi">10.1016/j.bbi.2018.03.022</article-id>
<article-id pub-id-type="manuscript">NIHMS970391</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A pilot study on immuno-psychiatry in the 22q11.2 deletion syndrome: A role for Th17 cells in psychosis?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vergaelen</surname>
<given-names>Elfi</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="corresp" rid="CR2">*</xref>
<xref ref-type="corresp" rid="CR1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schiweck</surname>
<given-names>Carmen</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="corresp" rid="CR1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Steeland</surname>
<given-names>Kristof Van</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Counotte</surname>
<given-names>Jacqueline</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veling</surname>
<given-names>Wim</given-names>
</name>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Swillen</surname>
<given-names>Ann</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A6">f</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Drexhage</surname>
<given-names>Hemmo</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Claes</surname>
<given-names>Stephan</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>University Psychiatric Center KU Leuven, University Hospital Leuven, Leuven, Belgium</aff>
<aff id="A2"><label>b</label>Center for Human Genetics, University Hospital Leuven, Leuven, Belgium</aff>
<aff id="A3"><label>c</label>Department of Immunology, Erasmus MC, Rotterdam, The Netherlands</aff>
<aff id="A4"><label>d</label>Parnassia Psychiatric Institute, The Hague, The Netherlands</aff>
<aff id="A5"><label>e</label>University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, The Netherlands</aff>
<aff id="A6"><label>f</label>Department of Human Genetics, KU Leuven, Leuven, Belgium</aff>
<author-notes>
<corresp id="CR1"><label>1</label>E. Vergaelen and C. Schiweck share first co-authorship.</corresp>
<corresp id="CR2"><label>*</label>Corresponding author at: Herestraat 49, 3000 Leuven, Belgium. <email>elfi.vergaelen@uzleuven.be</email> (E. Vergaelen).</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P37">Financial disclosures</p>
<p id="P38">H.A. Drexhage does not have conflicts of interest with commercial firms, except with IgNova which does not have any interest in this study. All other authors have no conflicts of interest to declare.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>70</volume>
<fpage>88</fpage>
<lpage>95</lpage>
<!--elocation-id from pubmed: 10.1016/j.bbi.2018.03.022-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P2">A growing body of evidence supports a role for immune alterations in Schizophrenia Spectrum Disorders (SSD). A high prevalence (25–40%) of SSD has been found in patients with 22q11.2 deletion syndrome (22q11.2DS), which is known for T-cell deficits due to thymus hypoplasia. This study is the first to explore the association between the T-cell subsets and psychotic symptoms in adults with 22q11.2DS.</p>
</sec>
<sec id="S2">
<title>Methods:</title>
<p id="P3">34 individuals (aged 19–38 yrs.) with 22q11.2DS and 34 healthy age- and gender matched control individuals were included. FACS analysis of the blood samples was performed to define T-cell subsets. Ultra-high risk for psychosis or diagnosis of SSD was determined based on CAARMS interviews and DSM-5 criteria for SSD. Positive psychotic symptom severity was measured based on the PANSS positive symptoms subscale.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P4">A partial T-cell immune deficiency in 22q11.2DS patients was confirmed by significantly reduced percentages of circulating T and T-helper cells. Significantly higher percentages of inflammatory Th1, Th17, and memory T-helper cells were found in adults with 22q11.2DS. Most importantly an increased Th17 percentage was found in adults with psychotic symptoms as compared to non-psychotic adults with 22q11.2DS, and Th17 percentage were related to the presence of positive psychotic symptoms.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P5">Given the literature on the role of T cells and in particular of Th17 cells and IL-17 in hippocampus development, cognition and behavior, these results support the hypothesis for a role of Th17 cells in the development and/or regulation of psychotic symptoms in 22q11.2DS. This pilot study underlines the importance to further study the role of T-cell defects and of Th17 cells in the development of psychiatric symptoms. It also supports the possibility to use 22q11.2DS as a model to study T-cell involvement in the development of SSD.</p>
</sec>
</abstract>
<kwd-group>
<kwd>22q11.2 deletion syndrome</kwd>
<kwd>Schizophrenia spectrum disorder</kwd>
<kwd>Th17 cells</kwd>
<kwd>T-cell immune deficiency</kwd>
<kwd>Psychosis</kwd>
<kwd>Neuro-inflammation</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>